Allarity Therapeutics IncChange company Symbol lookupSelect an option...ALLR Allarity Therapeutics IncTATT TAT Technologies LtdDARE Dare Bioscience IncREXR-C Rexford Industrial Realty IncAQNA Algonquin Power & Utilities CorpNAOV Nanovibronix IncIOT Samsara IncGSIT GSI Technology IncGME GameStop CorpCMBM Cambium Networks CorpGo
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Allarity Therapeutics, Inc. is a clinical-stage, precision medicine pharmaceutical company. It is advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its clinical program includes three anti-cancer assets in mid-stage clinical development and one anti-cancer asset in early-stage clinical development. Its programs and partnerships leverage its Drug Response Predictor technology to refine patient selection and improve clinical outcomes. It is focused on clinical development of three programs: dovitinib in combination with stenoparib for the second-line or later treatment of metastatic ovarian cancer; stenoparib as a monotherapy for ovarian cancer, and IXEMPRA as a monotherapy for metastatic breast cancer. Its dovitinib is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. Its IXEMPRA is a selective microtubule inhibitor, which has been shown to interfere with cancer cell division, to cell death.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| May 11, 2023 | Q1 2023 Earnings Release | -$4.43 | -$7.88 to -$7.88 | -- |
| March 13, 2023 | Q4 2022 Earnings Release | -$8.05 | -$0.417 to -$0.417 | -- |
| November 14, 2022 | Q3 2022 Earnings Release | -$23.80 | -$0.26 to -$0.25 | -- |
| August 22, 2022 | Q2 2022 Earnings Release | -$18.20 | -$0.42 to -$0.42 | -- |
Past Stock Splits
| Date | Event description | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| March 27, 2023 | 1:35 Stock Split | |||||||||
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.